Clinical outcomes of adjuvant taxane plus anthracycline versus taxane-based chemotherapy regimens in older adults with node-positive, triple-negative breast cancer: A SEER

Clinical outcomes of adjuvant taxane plus anthracycline versus taxane-based chemotherapy regimens in older adults with node-positive, triple-negative breast cancer: A SEER–Medicare study

Published:2023-05 Issue: Volume:185 Page:69-82
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Roy Savannah^ORCID,Lakritz Stephanie,Schreiber Anna R.^ORCID,Molina Elizabeth,Kabos Peter,Wood Marie,Elias Anthony^ORCID,Kondapalli Lavanya^ORCID,Bradley Cathy J.,Diamond Jennifer R.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference43 articles.

1. Breast cancer statistics, 2019;DeSantis;CA Cancer J Clin,2019

2. Triple-negative breast cancer: clinical features and patterns of recurrence;Dent;Clin Cancer Res,2007

3. Triple-negative breast cancer: epidemiological considerations and recommendations;Boyle;Ann Oncol,2012

4. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer registry;Bauer;Cancer,2007

5. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer;Haffty;J Clin Oncol,2006

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advocate-BREAST80+: A Comprehensive Patient and Advocate-Led Study to Enhance Breast Cancer Care Delivery and Patient-Centered Research in Women Aged ≥80 Years;Cancers;2024-07-09

2. Synergistic effects and competitive relationships between DOC and DOX as acting on DNA molecules: Studied with confocal Raman spectroscopy and molecular docking technology;Heliyon;2024-05

3. Major cardiovascular adverse events in older adults with early-stage triple-negative breast cancer treated with adjuvant taxane + anthracycline versus taxane-based chemotherapy regimens: A SEER-medicare study;European Journal of Cancer;2024-01